CFM
DAWN

Catalyst Funds Management’s Day One Biopharmaceuticals DAWN Stock Holding History

Catalyst Funds Management’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,200
Closed -$16.5K – 1367
2024
Q2 		$16.5K Sell
1,200
-1,200
-50% -$17.6K ﹤0.01% 743
2024
Q1 		$39.6K Buy
+2,400
New +$35.9K 0.01% 620

Other funds holding DAWN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catalyst Funds Management's DAWN Position: Q3 2024 in Review

Catalyst Funds Management sold out of Day One Biopharmaceuticals (DAWN) in Q3 2024, closing a stake of 1,200 shares — an estimated $16.5K sold.

Catalyst Funds Management first reported a position in DAWN in Q1 2024 and held it in 2 quarters. The position peaked at $39.6K in Q1 2024. 166 funds tracked by Wall St. Rank hold DAWN as of Q3 2024.

  • Catalyst Funds Management reported no remaining Day One Biopharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 1,200 Day One Biopharmaceuticals shares in Q3 2024, an estimated $16.5K.
  • Catalyst Funds Management first reported a position in Day One Biopharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Day One Biopharmaceuticals position peaked at $39.6K in Q1 2024.
  • 166 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q3 2024.

Based on Catalyst Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.